Share Price tanked for the "wrong" reason
It is not the "under performance" of Xanamen that is the issue, it is the "out performance" of the placebo - not expected, not "normal" and not understood
Whether it is the cohort, other drugs they were on, the length of the trial whatever, instead of broadly "flat lining", the placebo group has tracked the Xanamen Group. Suspect it is trial length and that is why it starts to out perform from circa week 4 on
Oversold big time - buyer at 2.9c yesterday
- Forums
- ASX - By Stock
- Ann: ACW XanaCIDD phase 2a trial topline results
Share Price tanked for the "wrong" reasonIt is not the "under...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
2.8¢ |
Change
-0.003(9.68%) |
Mkt cap ! $78.63M |
Open | High | Low | Value | Volume |
3.0¢ | 3.1¢ | 2.7¢ | $564.6K | 19.74M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 2004520 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 29247 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 2004520 | 0.027 |
14 | 2304588 | 0.026 |
25 | 4743643 | 0.025 |
9 | 2644096 | 0.024 |
6 | 870000 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 29247 | 1 |
0.029 | 1582665 | 9 |
0.030 | 2990884 | 14 |
0.031 | 2271835 | 7 |
0.032 | 1442122 | 8 |
Last trade - 12.53pm 13/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online